for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ajanta Pharma Ltd

AJPH.NS

Latest Trade

979.55INR

Change

-0.30(-0.03%)

Volume

24,756

Today's Range

975.20

 - 

985.90

52 Week Range

825.00

 - 

1,204.45

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
979.85
Open
980.90
Volume
24,756
3M AVG Volume
1.91
Today's High
985.90
Today's Low
975.20
52 Week High
1,204.45
52 Week Low
825.00
Shares Out (MIL)
87.70
Market Cap (MIL)
85,476.77
Forward P/E
20.36
Dividend (Yield %)
1.79

Next Event

Q3 2020 Ajanta Pharma Ltd Earnings Release

Latest Developments

More

India's Ajanta Pharma Sept-Quarter Profit Falls

India's Ajanta Pharma June-Qtr Consol PAT Rises

India's Ajanta Pharma March-Qtr Consol Profit Falls

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ajanta Pharma Ltd

Ajanta Pharma Limited is a holding company. The Company is a specialty pharmaceutical company engaged in developing, producing and marketing a range of branded and generic formulations. Its business includes branded generics in emerging markets of Asia and Africa, generics in the developed markets of the United States and Institutional sales. The branded generics business is spread in India and over 30 emerging countries across Africa, Commonwealth of Independent States (CIS), the Middle East and South East Asia. The Company serves a range of therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, cardiology, gynecology, orthopedics, pediatric, respiratory and general health products. Ajanta has six formulations manufacturing facilities located in India and 1 in Mauritius. In addition, the Company also has an API manufacturing facility located at Waluj, India. The Company's subsidiaries include Ajanta Pharma (Mauritius) Ltd., and Ajanta Pharma USA Inc.

Industry

Biotechnology & Drugs

Contact Info

Ajanta House,, Charkop, Kandivli West,

+91.22.66061000

http://www.ajantapharma.com/

Executive Leadership

Mannalal B. Agrawal

Non-Executive Chairman of the Board

Madhusudan B. Agrawal

Vice Chairman of the Board

Gaurang Shah

Compliance Officer, Senior General Manager - Legal, Company Secretary

Rajesh M. Agrawal

Joint Managing Director, Director

Yogesh M. Agrawal

Managing Director, Director

Key Stats

2.50 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

19.3K

2018

21.3K

2019

20.6K

2020(E)

23.3K
EPS (INR)

2017

57.580

2018

53.250

2019

43.960

2020(E)

48.200
Price To Earnings (TTM)
22.18
Price To Sales (TTM)
3.79
Price To Book (MRQ)
3.48
Price To Cash Flow (TTM)
18.18
Total Debt To Equity (MRQ)
3.06
LT Debt To Equity (MRQ)
1.44
Return on Investment (TTM)
15.68
Return on Equity (TTM)
13.28

Latest News

Latest News

BRIEF-India's Ajanta Pharma March Qtr Consol Profit Falls

* MARCH QUARTER CONSOL PROFIT 944.9 MILLION RUPEES VERSUS PROFIT 1.14 BILLION RUPEES YEAR AGO

BRIEF-Ajanta Pharma Says No Form 483 Issued By USFDA To Facility At Dahej

* SAYS FORMULATION FACILITY AT DAHEJ WAS INSPECTED BY US FDA FROM 5TH TO 9TH FEBRUARY

BRIEF-India's Ajanta Pharma Dec Qtr Consol Profit Rises

* DEC QUARTER CONSOL PROFIT 1.47 BILLION RUPEES VERSUS PROFIT 1.43 BILLION RUPEES YEAR AGO

BRIEF-Ajanta Pharma's Vice-Chairman​ Purushottam B. Agrawal Resigns

* SAYS PURUSHOTTAM B. AGRAWAL RESIGNS AS VICE-CHAIRMAN Source text: http://bit.ly/2kuqxWC Further company coverage:

BRIEF-India's Ajanta Pharma launches clonidine hydrochloride extended release tablets in U.S.

* Ajanta Pharma announces approval & launch of clonidine hydrochloride extended release tablets

BRIEF-India's Ajanta Pharma Sept-qtr consol profit rises marginally

* Sept quarter consol net profit 1.32 billion rupees versus 1.31 billion rupees year ago

BRIEF-India's Ajanta Pharma gets final approval for Entacapone tablets from U.S. FDA

* Says received the final approval for Entacapone tablets from US FDA

BRIEF-Ajanta Pharma says U.S. unit launches eletriptan hydrobromide tablets

* Says launched eletriptan hydrobromide tablets in US market through our wholly owned subsidiary, Ajanta Pharma USA Inc. Source text for Eikon: Further company coverage:

BRIEF-India's Ajanta Pharma June-qtr profit falls

* June quarter profit 947.9 million rupees versus 1.20 billion rupees year ago

BRIEF-Ajanta Pharma says Ganga Exports sold 2.7 mln shares of co

* Says Ganga Exports has sold 2.7 million equity shares of company representing 3.07 pct of paid up capital Source text for Eikon: Further company coverage:

BRIEF-Ajanta Pharma March-qtr consol profit rises

* March quarter consol net profit 1.14 billion rupees versus profit 1.09 billion rupees year ago

BRIEF-Ajanta Pharma's Dahej facility does not get form 483 after FDA inspection

* Ajanta Pharma Ltd says co's Dahej facility was inspected by FDA from April 3-7, 2017; no form 483 was issued Source text: [This is to inform you that Company's formulation facility at Dahej was inspected by US FDA from 3rd to 7th April, 2017. At the end of the inspection...

BRIEF-Ajanta Pharma's Paithan facility been issued one procedural related 483 by USFDA

* Says company's Paithan facility was recently inspected by US FDA and company has issued one procedural related 483.

BRIEF-Ajanta Pharma Dec-qtr consol net profit rises

* Dec quarter consol net profit 1.43 billion rupees versus profit 1.14 billion rupees year ago

BRIEF-Ajanta Pharma says haven't received any import alert by US FDA

* Ajanta Pharma clarifies on import alert received from USFDA

BRIEF-Ajanta Pharma gets import alert from USFDA for its Aurangabad plant - FDA website

* Gets import alert from USFDA for its Aurangabad plant - FDA website

BRIEF-Ajanta Pharma gets USFDA nod for Duloxetine Hydrochloride delayed release capsules

* Says Ajanta Pharma announces US FDA approval for Duloxetine Hydrochloride delayed release capsules

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up